The drug development pipeline for glioblastoma—A cross sectional assessment of the FDA Orphan Drug Product designation database

BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumour among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasin...

Descripción completa

Detalles Bibliográficos
Autores principales: Johann, Pascal, Lenz, Dominic, Ries, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263276/
https://www.ncbi.nlm.nih.gov/pubmed/34234357
http://dx.doi.org/10.1371/journal.pone.0252924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263276/
https://www.ncbi.nlm.nih.gov/pubmed/34234357
http://dx.doi.org/10.1371/journal.pone.0252924

Ejemplares similares